Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis
Research output: Contribution to journal › Journal article › Research › peer-review
Type 17 helper T cells have been suggested to play a pathological role in psoriasis. They secrete several proinflammatory cytokines, including interleukin-17A (also known as interleukin-17). We evaluated the safety and efficacy of ixekizumab (LY2439821), a humanized anti-interleukin-17 monoclonal antibody, for psoriasis treatment.
Original language | English |
---|---|
Journal | New England Journal of Medicine |
Volume | 366 |
Issue number | 13 |
Pages (from-to) | 1190-9 |
Number of pages | 10 |
ISSN | 0028-4793 |
DOIs | |
Publication status | Published - 2012 |
ID: 40205805